BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24954033)

  • 1. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
    Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
    Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
    Eadie LN; Saunders VA; Hughes TP; White DL
    Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
    Brendel C; Scharenberg C; Dohse M; Robey RW; Bates SE; Shukla S; Ambudkar SV; Wang Y; Wennemuth G; Burchert A; Boudriot U; Neubauer A
    Leukemia; 2007 Jun; 21(6):1267-75. PubMed ID: 17519960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
    Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
    Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
    Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
    Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
    Skoglund K; Boiso Moreno S; Jönsson JI; Vikingsson S; Carlsson B; Gréen H
    Pharmacogenet Genomics; 2014 Jan; 24(1):52-61. PubMed ID: 24322003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
    Davies A; Jordanides NE; Giannoudis A; Lucas CM; Hatziieremia S; Harris RJ; Jørgensen HG; Holyoake TL; Pirmohamed M; Clark RE; Mountford JC
    Leukemia; 2009 Nov; 23(11):1999-2006. PubMed ID: 19710702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
    Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
    Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
    Nakanishi T; Shiozawa K; Hassel BA; Ross DD
    Blood; 2006 Jul; 108(2):678-84. PubMed ID: 16543472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
    Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
    Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
    Shan XY; Chen BA; Xia GH; Xu WL; Ding JH; Gao C; Sun YY; Wang J; Cheng J; Zhao G; Bao W; Song HH; Gao F; Wang F; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):90-5. PubMed ID: 20137125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
    Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
    Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.
    Wang F; Wang XK; Shi CJ; Zhang H; Hu YP; Chen YF; Fu LW
    Molecules; 2014 Mar; 19(3):3356-75. PubMed ID: 24651611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Sen R; Natarajan K; Bhullar J; Shukla S; Fang HB; Cai L; Chen ZS; Ambudkar SV; Baer MR
    Mol Cancer Ther; 2012 Sep; 11(9):2033-44. PubMed ID: 22778153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.